Status: Recruiting
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative. The dose escalation is completed, Part 2 of the study is ongoing.
Participants needed: 55
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: DeuterOncologyUpdated: Apr 3, 2026Locations: 13
Eligibility criteria
18 years or older [+8]
tumour harbouring other known oncogenic mutations promoting tumour growth [+15]